Dr. Sato

Takami Sato, MD, Ph.D

Contact Dr. Sato

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
  2. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis
  3. Co-Targeting HGF/cMET Signaling with MEK Inhibitors in metastatic uveal melanoma
  4. Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma
  5. Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma. Comparison with Institutional Controls
  6. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment
  7. Immune check point inhibitors combination in melanoma: Worth the toxicity?
  8. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization
  9. Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography
  10. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells
  11. Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
  12. Biology of advanced uveal melanoma and next steps for clinical therapeutics
  13. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases
  14. Treatment strategies for clinically detectable metastatic uveal melanoma
  15. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
  16. Tumor necrosis factor-α blockade and development of uveal melanoma: Expected adverse effect or just coincidence?
  17. Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity
  18. Early arterial stasis during resin-based yttrium-90 radioembolization: Incidence and preliminary outcomes
  19. High-dose vincristine sulfate liposome injection (Marqibo) is not associated with clinically meaningful hematologic toxicity
  20. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial